Impact of disease progression on health-related quality of life (HRQOL): Updated results from the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line (1L) maintenance therapy in patients with newly diagnosed advanced ovarian cancer (aOC).
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Mark S. Shahin, Maria-Pilar Barretina-Ginesta, David M. O’Malley, Brigitte Honhon, Colleen C. McCormick, Sakari Hietanen, Roisin E. O’Cearbhaill, Giorgia Mangili, Richard G. Moore, Dominique Berton, Robert Allen Burger, Elena Ioana Braicu, Bradley J. Monk, Maria Jesús Rubio-Pérez, Noelle Cloven, Charlotte Aaquist Haslund, Thomas J Herzog, Luda Shtessel, Jonathan Lim, Antonio Gonzalez Martin
Institutions: Thomas Jefferson University, Abington Memorial Hospital, Institut Català d'Oncologia, Institut d'Investigació Biomèdica de Girona, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Grand Charleroi Hospital, Johns Hopkins University, Johns Hopkins Hospital, Turku University Hospital, Memorial Sloan Kettering Cancer Center, IRCCS Ospedale San Raffaele, University of Rochester Medicine, University of Rochester, Institut de Cancérologie de l'Ouest, University of Pennsylvania, Charité - Universitätsmedizin Berlin, Gynecologic Oncology Group, Florida Cancer Specialists & Research Institute, Hospital Universitario Reina Sofía, Aalborg University Hospital, Nordic Society of Gynecologic Oncology, University of Cincinnati, University of Cincinnati Medical Center, Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410812702